Journals / The European Research Journal / 2016 / Volume: 2 Issue: 3

Transapical transcatheter aortic valve implantation in a high-risk patient with aortic and mitral regurgitation: usage of the JenaValve™ system

Suleyman Surer(Department of Cardiovascular Surgery, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara)
İlker Ince(Department of Cardiovascular Surgery, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara)
İbrahim Duvan(Department of Cardiovascular Surgery, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara)
Cengizhan Bayyurt(Department of Cardiovascular Surgery, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara)
Ugursay Kiziltepe(Department of Cardiovascular Surgery, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara)
Pages
—
Publication Date
2016-11-04
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We performed a transapical transcatheter aortic valve implantation procedure using this system without any procedure-related complications in a 75-year-old woman with multiple co-morbidity factors, who had both mitral and aortic regurgitation, and low ejection fraction.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:JenaValve TM system is a second-generation transcatheter heart valve that provides a successful deployment not only in calcified stenotic aortic valves but also in non-calcified, severe regurgitant aortic valves.
📊
Key Findings & Data:JenaValve TM system is a second-generation transcatheter heart valve that provides a successful deployment not only in calcified stenotic aortic valves but also in non-calcified, severe regurgitant aortic valves.
💡
Conclusion & Impact:We performed a transapical transcatheter aortic valve implantation procedure using this system without any procedure-related complications in a 75-year-old woman with multiple co-morbidity factors, who had both mitral and aortic regurgitation, and low ejection fraction.
🔬Design:Case Report
📍Scope:Comprehensive Sample
⚙️Variables:Aortic regurgitation · mitral regurgitation · transcatheter aortic valve implantation

Abstract

JenaValve TM system is a second-generation transcatheter heart valve that provides a successful deployment not only in calcified stenotic aortic valves but also in non-calcified, severe regurgitant aortic valves. We performed a transapical transcatheter aortic valve implantation procedure using this system without any procedure-related complications in a 75-year-old woman with multiple co-morbidity factors, who had both mitral and aortic regurgitation, and low ejection fraction.

🔖

Cite This Article

Surer, S., Ince, İ., Duvan, İ., Bayyurt, C., Kiziltepe, U. (2016). Transapical transcatheter aortic valve implantation in a high-risk patient with aortic and mitral regurgitation: usage of the JenaValve™ system. The European Research Journal, Volume: 2 Issue: 3. https://doi.org/10.18621/eurj.2016.5000197998

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451-96.
  2. Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, et al. 2012 ACCF/ AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 2012;59:1200-54.
  3. Seiffert M, Bader R, Kappert U, Rastan A, Krapf S, Bleiziffer S, et al. Initial German experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation. JACC Cardiovasc Interv 2014;7:1168-74.